The Andrew Koff Lab: Publications

Visit PubMed for a full listing of Andrew Koff’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, and Koff A. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 10: 8226-43, 2015

Abbas Manji G, Singer S, Koff A, and Schwartz GK. Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book. 2015:213-8

Dickson MA, Schwartz GK, Keohan ML, D’Angelo SP, Gounder MM, Chi P, Antonescu CR, Landa J, Qin LX, Crago AM, Singer S, Koff A, and Tap WD. Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.

Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, and Koff A. ATRX is a novel regulator of therapy induced senescence in human cells. Nat. Comms, 8:386, 2017

Kovatcheva M, Klein ME, Tap WD, and Koff A. Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol 5:e1384882, 2018

Klein ME, Kovatcheva M, Davis LE, Tap WD, and Koff A. CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought. Cancer Cell, In Press

Kovatcheva M, Klein ME, and Koff A. Atropos seals cell fate: understanding the transition from quiescence into senescence. In Systems Biology of the Cell Cycle: Towards Integration with Cell Physiology. Ed. Matteo Barberis, Springer Verlag, Berlin. In press

Klein ME, Dickson MA, Antonescu C, Qin LX, Dooley SJ, Barlas A, Manova K, Schwartz GK, Crago AM, Singer S, Koff A, and Tap WD. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy induced senescence. Oncogene, in revision